{
  "docId": "019de077-2ede-72aa-ade1-9df6586a5c43",
  "docSlug": "07da8690ded5d079d6760889d2f598d8",
  "documentTitle": "BenevolentAI | Investor Presentation Deck | 31 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 31,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "why_now",
  "function": "argue_timing",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": "The slide uses a causal chain logic to connect market deal activity and clinical unmet needs to the value proposition of the drug.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de077-2ede-72aa-ade1-9df6586a5c43/16",
  "deckHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43",
  "deckJsonHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43.json",
  "deckAnchorHref": "/decks/019de077-2ede-72aa-ade1-9df6586a5c43#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.54
      },
      "kind": "callout",
      "text": "High unmet need for an alternative oral small molecule treatment option with improved safety profile AND efficacy in treatment of refractory patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ecc085f-12ee-4b92-ae53-48c6b753fdbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Recent deal activity in IBD driven by desire for oral small molecules (vs. more expensive biologics) and novel targets",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43bd25fa-d5cd-4779-9101-4612c93be5d8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.05,
        "y": 0.62
      },
      "kind": "list",
      "text": "Efficacy - 20-40% of Moderate-severe UC patients do not respond to anti-TNF; Safety - current treatments have many side effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33a6b4c0-370c-45bb-8fd3-c2fdbd3296e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.55,
        "y": 0.28
      },
      "kind": "list",
      "text": "Lilly/Morphic & Abbvie/Landos - oral small molecules; Merck / Prometheus & Abbvie/celsius - novel targets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ee9a5a2-af9e-4e08-851f-3cdc5cbc0124",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.68
      },
      "kind": "list",
      "text": "BEN-8744 dual effect, addresses: Patients' response to current treatments AND safety issues; BEN-8744 offers rational combination with all currently approved drug classes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67f1762e-6125-456e-92e0-aaaea634a493",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.27,
        "y": 0.15
      },
      "kind": "list",
      "text": "BEN-8744 will target moderate and severe UC/CD patients, addressing the unmet need left by existing therapies including: Patients' refractory to anti-TNFs or other biologics; Improved safety and tolerability profile compared to competitors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6aa5f6a9-7646-479c-9711-8f69e2626a4c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "paragraph",
      "text": "BEN-8744 is expected to provide an efficacious disease modifying oral treatment for UC/CD. Dual effect: barrier/inflammation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d65cfe0-421c-400c-a91d-1ef98a31eb3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "(1) Roda et al. Clin Transl Gastroenterol 2016; (2) Kobayashi et al Nat Rev Dis Primers 2020 and US FDA Drug Safety Communication 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b915c564-9ec5-487c-8edf-5ab7649a2d13",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "BEN-8744 (PDE10 inhibitor) - significant opportunity in IBD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5392e4bd-2e5f-421f-a79b-37595ef6e6d6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SWOT",
      "slug": "swot",
      "agent": null,
      "layer": "slide",
      "matchId": "a955a39b-a852-46a5-93d1-65a8cda2da0d",
      "evidence": "The list/bullet component describes the strengths and weaknesses of BEN-8744, including its potential as an oral small molecule treatment option.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "27285651-53a3-42fc-ab85-2421a2847349",
      "evidence": "Connects market deal activity and clinical unmet needs to the drug's value proposition.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 16,
      "from": 16,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "cd213991-b6ad-4532-a083-168c9a37beb2",
      "evidence": "The deck explains why now is the right time for BenevolentAI",
      "position": 2,
      "objective": "Explain why now is the right time for BenevolentAI",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}